Prot #BTI-203: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Recombinant Human Plasma Gelsolin With Standard of Care for Moderate-to-Severe ARDS Due to Pneumonia or Other Infections

Project: Research project

Project Details

StatusActive
Effective start/end date9/8/24 → 9/8/27

Funding

  • Ergomed Clinical Research Inc. (Prot #BTI-203 // Prot #BTI-203)
  • BioAegis Therapeutics, Inc. (Prot #BTI-203 // Prot #BTI-203)